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Abstract Human epidermal growth factor receptor 2 (HER2)
overexpression and amplification have been reported as pre-
dictive markers for HER2-targeted therapy in breast and gas-
tric cancer, whereas human epidermal growth factor receptor 3
(HER3) is emerging as a potential resistance factor. The aim of
this study was to perform a systematic review and meta-
analysis of the HER2 and HER3 overexpression and amplifi-
cation in biliary tract cancers (BTCs). An electronic search of
MEDLINE, American Society of Clinical Oncology (ASCO),
European Society of Medical Oncology Congress (ESMO),
and American Association for Cancer Research (AACR) was
performed to identify studies reporting HER2 and/or HER3
membrane protein expression by immunohistochemistry
(IHC) and/or gene amplification by in situ hybridization
(ISH) in BTCs. Studies were classified as Bhigh quality^
(HQ) if IHC overexpression was defined as presence of
moderate/strong staining or Blow quality^ (LQ) where Bany^
expression was considered positive. Of 440 studies screened,
40 met the inclusion criteria. Globally, HER2 expression rate
was 26.5 % (95 % CI 18.9–34.1 %). When HQ studies were
analyzed (n = 27 studies), extrahepatic BTCs showed a higher
HER2 overexpression rate compared to intrahepatic cholan-
giocarcinoma: 19.9 % (95%CI 12.8–27.1 %) vs. 4.8 % (95%
CI 0–14.5 %), respectively, p value 0.0049. HER2
amplification rate was higher in patients selected by HER2
overexpression compared to Bunselected^ patients: 57.6 %
(95 % CI 16.2–99 %) vs. 17.9 % (95 % CI 0.1–35.4 %),
respectively, p value 0.0072. HER3 overexpression (4/4 HQ
studies) and amplification rates were 27.9 % (95 % CI 9.7–
46.1 %) and 26.5 % (one study), respectively. Up to 20 % of
extrahepatic BTCs appear to be HER2 overexpressed; of
these, close to 60 % appear to be HER2 amplified, while
HER3 is overexpressed or amplified in about 25% of patients.
Clinical relevance for targeted therapy should be tested in
prospective clinical trials.
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1 Introduction
1.1 Background
The prognosis for patients with advanced biliary tract cancers
(BTCs) is very poor with a median overall survival of less than
12 months following treatment with systemic chemotherapy
[1]. The term BTCs refers to a heterogeneous group of dis-
eases encompassing cholangiocarcinoma (CC) [intrahepatic
cholangiocarcinoma (IHCC), extrahepatic cholangiocarcino-
ma (EHCC)], gallbladder carcinoma (GBC), and ampulla of
Vater carcinoma (AC). It is postulated that specific genetic and
molecular aberrations vary between these subtypes and thus
may provide predictive biomarkers of response to targeted
therapy. Unfortunately, unlike other solid tumors, targetable
biomarkers are lacking in BTCs and the cisplatin and
gemcitabine combination remains gold standard first-line
treatment worldwide in patients with advanced disease [2],
with no proven benefit from targeted therapies as yet
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identified [3, 4]. Thus, biomarkers of response are urgently
required in this challenging disease. The human epidermal
growth factor receptor 2 (HER2), which belongs to the
ErbB/(HER) family of receptor tyrosine kinases (TK), is a
well-described predictive biomarker for anti-HER2 therapy
in breast and gastric cancer [5, 6]. To date, previous clinical
reports have suggested some activity of trastuzumab (an anti-
HER2 monoclonal antibody) in association with chemothera-
py in HER2 upregulated BTCs [7–10]. In contrast, trials ex-
ploring the role of anti-EGFR monoclonal antibodies and
EGFR tyrosine kinase inhibitors (TKIs) have resulted in dis-
appointing and/or conflicting findings [11–14]. This system-
atic review aims to quantify the reported HER2 and HER3
expression rates in BTC in order to provide useful data for
the development of potential novel systemic-targeted strate-
gies for use in future clinical trials.
1.2 HER2/HER3 pathway
The HER family consists of four receptors [HER1 (EGFR),
HER2, HER3, and HER4] with similar structure, consisting of
four main parts: an extracellular ErbB ligand-binding domain,
a single transmembrane lipophilic segment, an intracellular
tyrosine kinase domain, and an intracellular C-terminal tail
[15]. The extracellular ligand-binding region contains four
domains (I–IV): domains I and III recognize and bind their
corresponding ligands and domain II mediates receptor dimer-
ization, whereas domain IV, interacting with domain II, leads
to a negative feedback on the dimerization process [16].
Ligand binding to the extracellular domain results in receptor
homo- or heterodimerization, a critical step in HER family-
mediated signaling. Dimerization induces the activation of the
intrinsic tyrosine kinase domain, by phosphorylation of spe-
cific tyrosine residues, leading to the activation of different
downstream signaling cascades, including the mitogen-
activated protein kinase (MAPK) proliferation pathway and
phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB
or Akt) pro-survival pathway [17, 18] (Fig. 1).
HER2 and HER3 are known to have characteristics distinct
from other HER family receptors. HER2 lacks a specific li-
gand, so it can form heterodimers only if it is trans-activated
from other activated HER receptors (such as EGFR, HER3,
and HER4) [19]. In addition to abnormal overexpression,
HER2 is also able to spontaneously homodimerize [16]. In
contrast to HER2, HER3 can bind multiple ligands
(neuregulins) [20] but it lacks a functioning kinase domain
[21] and is, therefore, unable to homodimerize and to induce
downstream signaling pathway activation on its own.
However, in the presence of HER3 ligands, HER3 may pro-
mote the kinase activity of EGFR or HER2 and thereby induce
phosphorylation of the HER3 C-terminal tail inducing the
PI3K/Akt pathway activation by creating heterodimers [20].
Although all four HER family receptors are capable of
dimerizing with each other, HER2 is the preferred dimeriza-
tion partner [19] and the HER2–HER3 dimer seems to be the
most potent HER family dimer [22, 23]. Finally, HER3 has the
ability to dimerize with both HER family members and non-
HER family members such as mesenchymal epithelial transi-
tion (MET) receptor [24, 25], contributing to anti-HER2 ther-
apy resistance. Thus, dysregulation of HER-mediated signal-
ing pathways, through this complex mechanism, results in the
growth and spread of cancer cells.
1.3 HER2 and HER3 determination
The most commonly used methods to determine the HER2 and
HER3 status, in formalin-fixed paraffin-embedded tissue, are
(a) immunohistochemistry (IHC), which measures the number
of HER2 and HER3 receptors on the cell surface and therefore
detects receptor overexpression and (b) fluorescence or chro-
mogenic in situ hybridization (FISH and CISH, respectively),
which detects gene amplification by measuring the number of
copies of the HER2 andHER3 gene in the nuclei of tumor cells.
Currently, standard clinical practice guidelines for HER2
status assessment are available for breast and gastric cancer
only. In contrast, because HER3 status is not routinely ana-
lyzed, IHC and ISH techniques for assessing HER3 status
have not been standardized.
The IHC and FISH scoring criteria are different for breast and
gastric cancer [26, 27], reflecting intrinsic biological differences,
including higher heterogeneity of HER2 membranous immuno-
reactivity in gastric cancer. In addition, in gastric cancer, different
scales are used depending on the nature of the diagnostic speci-
men (surgical specimen vs. biopsy sample) [6, 27]; these criteria
are summarized in Table 1.
Data from published series of HER2 and HER3 expression
varies both in terms of methodology, reporting, and subse-
quent utility. We therefore set out to undertake a systematic
review (i.e., pooled analysis of HER2 and HER3 expression in
published BTC series), to provide a Bsummary estimate^ of
such expression, with a view to informing the design of future
clinical trials.
2 Methods
2.1 Study selection criteria
Eligible studies were those which met the following inclusion
criteria: (1) studies reporting membrane expression by IHC
and/or amplification by ISH of HER2 and/or HER3 data in
human BTC tissue; (2) studies in which data for invasive/
infiltrating tumors was available; and (3) original article publi-
cations (or abstracts, in the absence of a full publication); stud-
ies reporting preclinical data, reviews, and case reports were
excluded. Studies in which data for the subgroup of patients
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with BTC was not available (i.e., when only combined results
were reported including non-BTC primary disease sites such as
hepatocellular carcinoma, pancreatic carcinoma, or neuroendo-
crine tumors) were excluded. Other exclusion criteria were (1)
studies reporting results which included mixed pathological
entities [i.e., mixed hepato-cholangiocarcinoma, mixed adeno-
neuroendocrine carcinomas (MANEC)]; (2) publications in
which techniques other than IHC and ISHwere employed (with
no data for IHC or ISH available); and (3) studies in which
HER2 pathway analysis was performed following successful
anti-HER2 therapy were excluded due to patient selection bias.
When studies reporting the same series of patients were identi-
fied (Bduplicate data^), the study with the greater number of
informative patients for the primary end point of this review
was selected for inclusion.
2.2 Search strategy
A systematic search was conducted utilizing the PubMed/
MEDLINE electronic data base (updated 20 November
2015); no dates of publication or language limits were applied.
The following two search strategies were employed:
1. her2[All Fields] AND ((Bcholangiocarcinoma^[MeSH
Terms] OR Bcholangiocarcinoma^[All Fields]) OR
((Bbiliary tract^[MeSH Terms] OR (Bbiliary^[All Fields]
AND Btract^[All Fields]) OR Bbiliary tract^[All Fields])
AND (Bcarcinoma^[MeSH Terms] OR Bcarcinoma^[All
Fields])) OR ((Bgallbladder^[MeSH Terms] OR
Bgallbladder^[All Fields]) AND (Bcarcinoma^[MeSH
Terms] OR Bcarcinoma^[All Fields])) OR (ampullary[All
Fields] AND (Bcarcinoma^[MeSH Terms] OR
Bcarcinoma^[All Fields])) OR ((Bcarcinoma^[MeSH
Terms] OR Bcarcinoma^[All Fields]) AND (Bampulla of
vater^[MeSH Terms] OR (Bampulla^[All Fields] AND
Bvater^[All Fields]) OR Bampulla of vater^[All Fields])));
2. her3[All Fields] AND ((Bcholangiocarcinoma^[MeSH
Terms] OR Bcholangiocarcinoma^[All Fields]) OR
((Bbiliary tract^[MeSH Terms] OR (Bbiliary^[All Fields]
AND Btract^[All Fields]) OR Bbiliary tract^[All Fields])
AND (Bcarcinoma^[MeSH Terms] OR Bcarcinoma^[All
Fields])) OR ((Bgallbladder^[MeSH Terms] OR
Bgallbladder^[All Fields]) AND (Bcarcinoma^[MeSH
Te rm s ] OR Bc a r c i n oma^[A l l F i e l d s ] ) ) OR
(ampullary[All Fields] AND (Bcarcinoma^[MeSH
Te rm s ] OR Bc a r c i n oma^[A l l F i e l d s ] ) ) OR
((Bcarcinoma^[MeSH Terms] OR Bcarcinoma^[All
Fields]) AND (Bampulla of vater^[MeSH Terms] OR
(Bampulla^[All Fields] AND Bvater^[All Fields]) OR
Bampulla of vater^[All Fields]))) OR ((Breceptor, erbb-
2^[MeSH Terms] OR Bgenes, erbb-2^[MeSH Terms])
AND (((Bcholangiocarcinoma^[MeSH Terms] OR
Bcholangiocarcinoma^[All Fields]) OR ((Bbiliary
tract^[MeSH Terms] OR (Bbiliary^[All Fields] AND
Btract^[All Fields]) OR Bbiliary tract^[All Fields]) AND
(Bcarcinoma^[MeSH Terms] OR Bcarcinoma^[All
Fields])) OR ((Bgallbladder^[MeSH Terms] OR
Bgallbladder^[All Fields]) AND (Bcarcinoma^[MeSH
Te rm s ] OR Bc a r c i n oma^[A l l F i e l d s ] ) ) OR
(ampullary[All Fields] AND (Bcarcinoma^[MeSH
Fig. 1 HER2/HER3 pathway
and targeted therapy interaction
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Te rms ] OR Bc a r c i noma^[A l l F i e l d s ] ) ) ) OR
((Bcarcinoma^[MeSH Terms] OR Bcarcinoma^[All
Fields]) AND (Bampulla of vater^[MeSH Terms] OR
(Bampulla^[All Fields] AND Bvater^[All Fields]) OR
Bampulla of vater^[All Fields])))).
Meeting abstracts from the American Society of Clinical
Oncology (ASCO), European Society of Medical Oncology
Congress (ESMO), and American Association for Cancer
Research (AACR), presented over the last 5 years (2010–
2015), were also reviewed using the following keywords:
Bher2^ OR Bher3^ AND (Bcholangiocarcinoma,^ Bbiliary tract
carcinoma,^ Bgallbladder carcinoma,^ Bampullary carcinoma,^
Bcarcinoma of ampulla of vater^).
Reference lists of eligible studies were cross-checked man-
ually to identify potentially eligible articles.
2.3 Primary and secondary objectives
The primary objective of this systematic review and meta-
analysis was to assess the prevalence of HER2 overexpression
Table 1 Standardized guidelines
for HER2 analysis, adjusted from
2013 ASCO/CAP guidelines for
the HercepTest™ scoring system
in breast cancer [26] and
standardized guidelines (for both
surgical and biopsy specimen) for
gastric adenocarcinoma [6, 27]
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Breast cancer HER2 FISH testing (gene copy number and HER2-to-CEP17 ratio) positive: HER2 gene copy
number is greater than 6.0 (single probe) and in case of HER2 2+ if either HER2/CEP17 ratio
is ≥2.0 regardless gene copy number or if HER2/CEP17 ratio is <2.0 with an average HER2
copy number ≥6.0 (dual probe)
Gastric
cancer
FISH amplified (positive): IHC/HER2 2+ tumor samples are considered FISH amplified if
HER2/CEP17 ratio is ≥2
IHC immunohistochemistry, ISH in situ hybridization
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(measured by IHC) in patients with BTC, with the primary
end point being mean HER2 expression rate.
Secondary objectives included HER2 amplification (mea-
sured by ISH) both in the whole population (Bunselected
population^) and in the population of patients with HER2
overexpression by IHC (Bselected population^) and HER3
overexpression (measured by IHC) and amplification (mea-
sured by ISH). HER2 and HER3 expression and amplification
were analyzed by primary tumor site; HER2 expression was
also analyzed by quality of expression assessment (Bhigh
quality^ vs. Blow quality^) and by region (Western vs.
Asian). Correlation between HER2 and HER3 expression
and between HER2 expression and HER2 amplification (in
Bunselected population^) was also assessed.
2.4 Data collection
Eligibility for each of the studies was assessed by one of the
authors (SG); queries were discussed with a second author
(AL). Same process was followed for data collection. The
total number of patients in each study together with numerator
and denominator for each one of the reported rates were
collected.
In order to perform the planned subgroup analyses, the
following additional data were extracted from manuscripts
(if available): primary site (CC, IHCC, EHCC, GBC, or AC)
and ethnicity/region of patients involved in the study (Western
vs. Asian). Tumor site was also subdivided into extrahepatic
BTCs (EH-BTCs) which include EHCC, GBC, and AC and
IHCC. In addition, eligible studies were classified according
to the quality of HER expression assessment: studies were
considered to be Bhigh quality^ (HQ) when moderate/strong
HER2/HER3 overexpression was used to classify tumors,
whereas studies were classified as Blow quality^ (LQ) when
the HER2/HER3 overexpression threshold was not specified
and/or not reported by authors or when Bany^ HER2/HER3
expression (including IHC 1+) was used.
For assessment of HER2 amplification rate, studies were
classified according to the population in which ISH was per-
formed: Bunselected population^ referred to studies in which
the ISH was performed in the whole study population regard-
less of IHC results, while the term Bselected population^ was
employed for those studies in which ISH was performed only
in patients with overexpression of HER2 according to IHC.
2.5 Statistical analysis
The Stata/MP v.12 package was used for the statistical analy-
sis. Mean and 95 % confidence intervals (95 % CI) were
calculated for reported HER2/HER3 expression/amplification
rate. Mean HER2/HER3 expression/amplification rates were
calculated for each one of the prespecified subgroup analyses:
primary tumor site, region, quality of HER2 expression
assessment, and population in which ISH was performed.
All these analyses were repeated for each one of the tumor
sites. Shapiro-Wilks normality test was performed for contin-
uous variables; based on these results, parametric/
nonparametric tests were used for the statistical analysis of
the results and comparison of expression/amplification rates
between subgroups employing Student’s t test or Wilcoxon
rank-sum test as appropriate. Correlation was assessed using
Pearson or Spearman’s rho as appropriate, according to
whether variables followed a normal distribution or not.
3 Results
3.1 Eligible studies
Figure 2 summarizes the PRISMA flow diagram for selection
of eligible studies [28]; a total of 454 results were obtained
from the searches in PubMed/MEDLINE (n = 105), ASCO
(n = 11), ESMO (n = 103), and AACR (n = 235). Of these, 14
were duplicates and 389 did not meet the inclusion criteria and
were therefore excluded. Of the 51 studies which appeared to
be eligible after the initial screen, a full-text search was carried
out. In addition, seven full-text records through cross-
reference checking were identified for a total of 58 studies
assessable for eligibility. Eighteen studies were excluded after
the full-text review as per our inclusion/exclusion criteria: 11
studies did not report an optimal distinction between cytoplas-
mic and membrane HER2/HER3 staining [29–39]; one study
employed a method other than IHC and/or ISH for evaluating
HER2/HER3 expression with no IHC/ISH data reported [40];
three studies reported HER2 analysis following successful
targeting therapy and were therefore excluded due to selection
bias [10, 41, 42]; one study reported joined results for BTCs
and pancreatic cancer with no specific data for BTC patients
[43]; one study did not report which member of the HER
family was being assessed [44]; and one study reported
Bduplicate data^ [45].
3.2 Patient population
Forty studies were included in the final analysis, reporting a
total of 3839 patients with a diagnosis of BTC [46–85]
(Table 2). All studies were retrospective series, with a median
number of 53 patients per study (range 6–804).
According to the primary tumor site, the number of studies
and number of patients reported were as follows: CC (24
studies; 2102 patients; 55 % of all patients reported), IHCCs
(13 studies; 924 patients; 24% of all patients reported; 44% of
all CC patients), EHCCs (12 studies; 920 patients; 24 % of all
patients reported; 44 % of all CC patients), GBCs (15 studies;
1026 patients; 27 % of all patients reported), and ACs (8
studies; 303 patients; 8 % of all patients reported). In seven
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studies (258 patients; 7 % of all patients reported; 12 % of all
CC patients), the type of CC (IHCC vs. EHCC) was not spec-
ified. In four studies (408 patients; 10 % of all patients report-
ed), the type of BTC was not specified. Eighteen out of 40
(45 %) studies were conducted in Western countries and 17
(43 %) in Asian population, while the remaining 5 (12 %)
studies were mixed or not specified (Table 2).
3.3 HER2 expression (IHC)
Thirty-eight studies reported HER2 positivity assessed by
IHC (Table 3); two studies did not perform HER2 IHC anal-
ysis [66, 85]. Technical details regarding this assessment were
available for 37 of the 38 studies: in the remaining study, this
data was not available [71]. The most commonly used (23 of
37 studies; 62 %) anti-HER2 antibody was polyclonal
(Dako®, Dakopatts®, Nichirei®, or Zymed Lab®), followed
by monoclonal antibody in 13 studies (35 %) (Triton
Biosciences Inc.®, Immunotech®, DAKO®, Oncogene®,
Zymed Lab®, Carpinteria®, Ventana®, or Novocastra®); this
information was not available in one study (3 %). HER2 ex-
pression was qualitatively analyzed in 5 out of 37 (14 %)
studies, while a semiquantitative score, estimating the fraction
of positive cells, was used in 32 studies (86 %) (Table 3).
Globally, the mean HER2 expression rate was 26.5 %
(95 % CI, 18.9–34.1 %; Table 4). There were no statistically
significant differences between regions (Asian mean HER2
expression rate 28.4 % (95 % CI 14.5–42.3 %) vs. Western
19.7% (95%CI 10.1–29.2%); p value 0.4936; Table 4).With
respect to the quality of HER2 expression assessment, LQ
studies (11 studies; 27 % of all studies reporting HER2-IHC
data) had a significantly higher mean HER2 expression rate
compared to HQ studies (27 studies; 68 % of all studies
reporting HER2-IHC data): 41.7 % (95 % CI 22.9–60.5 %)
vs. 20.3 % (95 % CI 13.3–27.4 %), respectively, p value
0.0336; Table 4.
In all 38 studies, no differences in HER2/IHC expression
rates were found between tumor sites when considering all
studies, regardless of the quality of HER2 expression assess-
ment (Table 4). In contrast, when only HQ studies were con-
sidered, the mean HER2 overexpression rate in EH-BTCs was
statistically significantly higher to IHCCs (Table 4).
Moreover, mean HER2 overexpression rate was statistically
significantly higher in EHCCs compared to IHCCs and in
GBCs compared to IHCCs, whereas there was only a marginal
difference between ACs and IHCCs (Table 4).
3.4 HER2 amplification (ISH)
HER2 amplification analysis was performed in 16 studies:
applying FISH and CISH in 13 (81 %) and 3 (19 %) studies,
respectively (Table 3). Mean HER2 amplification rate was
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Fig. 2 PRISMA flow diagram
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Table 2 HER2 and/or HER3 expression by immunohistochemistry (IHC) and/or amplification by in situ hybridization (ISH) in biliary tract
carcinomas
Study Country N Primary HER2/IHC HER2/ISH HER3/IHC HER3/ISH
N % N % N % N %
Brunt EM USA (Western) 6 CC 4/6 66.7 NR NR NR
Collier JD 1992 UK (Western) 10 CC 0/10 0 NR NR NR
Lei S 1995 USA (Western) 6 AC 2/6 33.3 NR NR NR
Chow NH 1995 Taiwan (China) (Asian) 18 IHCC 5/18 27.8 NR NR NR
18 AC 5/18 27.8 NR NR NR
11 GBC 7/11 63.6 NR NR NR
Vaidya P 1996 Japan (Asian) 14 EHCC 10/14 71.4 NR 4/14 28.6 NR
13 AC 9/13 69.2 NR 4/13 30.8 NR
Terada T 1998 Japan (Asian) 47 CC 33/47 70 NR NR NR
Kim YW 2001 Not specified 71 GBC 33/71 46.5 NR NR NR
Ajiki T 2001 Japan (Asian) 30 AC 7/30 23 NR NR NR
Ukita Y 2002 Japan (Asian) 22 IHCC 18/22 82 22/22 100 NR NR
Endo K 2002 Japan, Thailand, USA (n/a) 71 CC 21/71 29.6 NR NR NR
Altimari A 2003 Italy (Western) 48 IHCC 2/48 4 2/48 4 NR NR
Matsuyama S 2004 Japan (Asian) 43 GBC 4/43 9.4 NR NR NR
KIM HJ 2005 South Korea (Asian) 20 CC 5/20 25 NR NR NR
Nakazawa K 2005 Japan (Asian) 28 IHCC 0/28 0 NR NR NR
78 EHCC 4/78 5.1 NR NR NR
89 GBC 14/89 15.7 NR NR NR
26 AV 3/26 11.5 NR NR NR
71 BTC – 15/71 21.1 – –
19 BTC – 15/19 79 – –
Settakorn J 2005 Australia/Thailand (n/a) 31 IHCC 10/31 32.3 NR NR NR
Ogo Y 2006 Japan (Asian) 72 BTCs 47/72 65 NR NR NR
Kim JH 2007 South Korea (Asian) 55 EHCC 16/55 29.1 10/55 18.1 NR NR
Kawamoto T 2007 USA/Chile (Western) 21 IHCC 7/21 33.3 0/14 0 NR NR
16 EHCC 5/16 33.3 3/14 21.4 NR NR
77 GBC 24/77 31.2 14/67 20.9 NR NR
Yoshikawa D 2008 Japan (Asian) 106 IHCC 1/106 0.9 NR NR NR
130 EHCC 11/130 8.5 NR NR NR
Miyahara n 2008 Japan (Asian) 51 GBC 16/51 31 4/16 25 NR NR
Joo HH 2007 South Korea (Asian) 112 BTCs 5/112 4.5 NR NR NR
Puhalla H 2007 Austria (Western) 55 GBC 7/55 13 NR NR NR
Kaufmann M 2008 USA (Western) 16 GBC 1/16 6.3 NR NR NR
Baumhoer D 2008 Switzerland, Germany, Italy (Western) 82 AV NR 5/82 6 NR NR
Choi HJ 2009 Not specified 50 IHCC 36/50 72 NR NR NR
Aloysius MM 2009 UK (Western) 29 EHCC 0/29 0 NR NR NR
22 AV 0/22 0 NR NR NR
Harder J 2009 Germany (Western) 124 BTCs 25/124 20.2 6/25 24 NR NR
Shafizadeh N 2010 USA (Western) 26 IHCC 0/26 0 NR NR NR
19 EHCC 2/19 10.5 NR NR NR
6 GBC 0/6 0 NR NR NR
Pignochino Y 2010 Italy (Western) 17 IHCC 0/10 0 NR NR NR
19 EHCC 4/19 21 2/4 50 NR NR
13 GBC 1/10 10 1/1 100 NR NR
Toledo C 2012 Chile (Western) 12 GBC 4/12 33 0/12 0 NR NR
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30.1 % (95 % CI 11.7–48.5 %) when all BTCs were analyzed
together (Table 4). When all studies were included (regardless
of applying ISH for Bselected^ or Bunselected^ population),
mean HER2 amplification rate was statistically significantly
higher in patients with EH-BTCs compared to IHCCs
(Table 4). Interestingly, the mean HER2 amplification rate
was higher in the five studies [59, 68, 72, 73, 78] in which
ISH test was performed in Bselected^ population when com-
pared to the 12 studies in which ISH test was applied to
Bunselected population^ only [17.9 % (95 % CI 0.1–35.4 %)
vs. 57.6 % (95 % CI 16.2–99 %), p value 0.0072] [55, 56, 59,
63, 64, 66, 77, 80–83, 85] (Table 4). Nakazawa et al. reported
data from 221 patients, 71 of whom had FISH testing per-
formed: meaningful differences in HER2 amplification rate
were shown between Bunselected^ [15/71 (21 %)] and
Bselected^ [15/19 (79 %)] populations [59] (Table 2).
3.5 Correlation between HER2 expression
and amplification
Ten studies [55, 56, 59, 63, 64, 77, 80, 82, 83, 85] and five
studies [59, 68, 72, 73, 78] had data for both HER2 expression
and amplification in the Bunselected^ and Bselected^ popula-
tion, respectively. While no statistically significant correlation
was observed in studies with the Bselected^ population (five
studies; Spearman rho = −0.9; p value 0.037), a better corre-
lation (although not statistically significant) was shown in
Bunselected^ patients (10 studies; Spearman rho 0.38; p value
0.2763) (Fig. 3).
3.6 HER3 expression and amplification
HER3 expression rate was reported in four studies in which
different commercially available antibodies were used
(Novocastra®, Santa Cruz®, or Spring Bioscience®). All four
studies had a HQ HER3 expression assessment (Table 3). The
pooled mean overall HER3 overexpression rate was 27.9 %
(95 % CI 9.7–46.1 %) [51, 76, 81, 83]; only one study report-
ed HER3 amplification rate (26.5 %) [83] (Table 2).
Further subgroup analyses for HER3 expression and am-
plification were not possible due to limited number of studies.
3.7 Correlation between HER2 and HER3 overexpression
All of the four studies with HER3 expression data had HER2
expression data available for correlation analysis [51, 76, 81,
83]. No statistically significant correlation was identified be-
tween HER2 and HER3 overexpression (four studies;
Spearman rho = 0.2; p value 0.8) (Fig. 4).
4 Discussion
The present systematic review and meta-analysis found that
there is a higher moderate/strong HER2 expression rate
(~20 %) in extrahepatic biliary tract carcinomas than in
IHCC (<5 %). In a previous meta-analysis, Wiggers et al. also
reported a statistically significant higher expression of HER2
in EHCC [risk ratio 0.22 (95 % CI, 0.07–0.65)] than in IHCC
Table 2 (continued)
Study Country N Primary HER2/IHC HER2/ISH HER3/IHC HER3/ISH
N % N % N % N %
Kumari N 2012 India (Asian) 104 GBC 14/104 13.4 NR NR NR
Lee HJ 2012 South Korea (Asian) 230 EHCC 13/224 6 NR 90/230 39 NR
Roa Iván 2013 Chile (Western) 187 GBC 62/187 31.11 NR NR NR
Wang W 2014 China (Asian) 58 IHCC 0/90 0 0/90 0 NR NR
94 EHCC 4/90 4.4 3/94 3.5 NR NR
Graham RP 2014 USA (Western) 100 BTCs 3/100 3 3/3 100 NR NR
Yang X 2014 China (Asian) 65 IHCC 0/65 0 0/65 0 8/65 12.3 NR
110 EHCC 5/110 4.5 8/108 7.4 13/110 11.8 NR
Kawamoto T 2015 USA 47 GBC 15/47 32 8/47 17 16/47 34 12/47 26
Japan (n/a) 66 CC 15/66 23 15/66 23 19/66 29 18/66 27
Hechtman J 2015 USA (Western) 106 AC 27/106 25.5 13/100 13 NR NR
Oliveira Fernandes VT 2015 Brazil (Western) 38 CC 11/38 30 NR NR NR
Holcombe RF 2015 USA (Western) 126 EHCC NR NR 18 NR NR
434 IHCC NR NR 1.5 NR NR
244 GBC NR NR 15 NR NR
CC cholangiocarcinoma, IHCC intrahepatic cholangiocarcinoma EHCC extrahepatic cholangiocarcinoma, GBC gallbladder carcinoma, AC carcinoma
of ampulla of Vater, BTCs biliary tract carcinomas, NR not reported, n/a not applicable
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[86]. However, this work was based on a smaller number of
studies (five) detecting HER2 expression in only IHCC and
EHCC, excluding GBC and AC, and did not provide any
information about ISH testing. Subgroup analysis by site of
primary in the current study suggested that HER2 overexpres-
sion was higher in EHCC, GBC, and AC tumors than in
IHCCs [of note, this difference was not statistically significant
between the group of IHCC and ACs, probably due to a small-
er sample size of this subgroup (303 patients)].
Interestingly, in the IHC Bselected population^ (patients
with moderate/strong expression by IHC), HER2 amplification
rate was found to be ~60 %. Therefore, these findings (moder-
ate/strong HER2 expression rates in EH-BTCs and FISH rates
in IHC Bselected^ patients) suggest around 10–20 % of EH-
BTCs can be virtually considered HER2 upregulated. In a re-
cent case series of 211 consecutive GBC tumors, 16.6 % of
Table 4 HER2 expression and
amplification results in biliary
tract carcinomas
HER2 status No. of
studies




Overall expression by IHC All 38 26.5 % (18.9–34.1 %)
By ethnicity Asian 17 28.4 % (14.5–42.3 %) Ref
Western 16 19.7 % (10.1–29.2 %) 0.4936
By IHC assessment (quality) Low quality
(LQ)
11 41.7 % (22.9–60.5 %) Ref
High quality
(HQ)
27 20.3 % (13.2–27.5 %) 0.0336
By site of primary (HQ studies
only)
IHCC 8 4.8 % (0–14.5 %) Ref
EH-BTC 28 19.9 % (12.8–27.1 %) 0.0049
EHCC 11 17.4 % (3.4–31.4 %) 0.0134
GBC 12 19.1 % (11.2–26.8 %) 0.0123
AC 5 27.9 % (0–60.7 %) 0.0642
Overall amplification by ISH All 16 30.1 % (11.7–48.5 %)
By site of primary IHCC 6 17.6 % (0–60.1 %) Ref
EH-BTC 14 22.5 % (7.9 %–37.2 %) 0.0468
By patient selection Unselected 12 17.9 % (0.1–35.4 %) Ref
Selected 5 57.6 % (16.2–99 %) 0.0072
LQ low quality, HQ high quality, ISH in situ hybridization, IHCC intrahepatic cholangiocarcinoma, EHCC
extrahepatic cholangiocarcinoma, EH-BTCs extrahepatic biliary tract cancers, GBC gallbladder carcinoma, AC
ampulla of Vater carcinoma, Ref category used as reference for comparisons
Bold-italics represent statistically significant results
Fig. 3 Correlation between
HER2 expression and
amplification
152 Cancer Metastasis Rev (2017) 36:141–157
tumors were globally found to be HER2 positive when IHC3+
and IHC 2+/FISH-amplified tumors were considered altogether
[87]. According to international HER2 assessment criteria used
for breast and gastric cancer [6, 26, 27], it may be assumed that
BTCs scoring 3+ on immunohistochemistry should be
interpreted as positive, while the application of in situ hybridi-
zation (fluorescence or chromogenic) could be carried out only
in tumors with an ambiguous (IHC 2+) score.
These results, in addition to some preclinical data demon-
strating that constitutive overexpression of activated HER2 can
result in cholangiocarcinoma development [88], provide some
support that the HER2 protein may play an important role in
extrahepatic biliary carcinogenesis. Consequently, the HER2
pathway may be considered as a potential actionable target in
EH-BTCs. Inhibition of HER2-mediated signaling is an
established therapeutic strategy in HER2-positive breast and
gastric cancer in which HER2 overexpression rates (up to
20 %) are similar to that found in EH-BTCs [26, 89]. Anti-
HER2 therapy options might include the antibodies
trastuzumab, pertuzumab, or trastuzumab emtansine (T-DM1)
or the small-molecule, orally active, TKI, lapatinib [6, 90, 91].
Beyond HER2, in BTC, other biomarkers might be in-
volved in cancer pathogenesis, prognosis, and resistance to
therapy. In the current meta-analysis, approximately one in
four patients had moderate/strong expression of HER3 or
HER3 gene amplification. Most interestingly, HER2/HER3
co-expression in BTCs ranges from 9 to 53 % [76, 83] and
has been demonstrated to be frequently associated with phos-
phorylation (activation) of HER2 and AKT [83]. HER3 is
often correlated with poorly differentiated biliary tumors
[81] and appears to be a poor prognostic factor in EHCCs
[76], whereas the prognostic meaning of HER2 has not been
completely clarified [79, 87]. Interestingly, the combination of
pertuzumab and trastuzumab has been reported to induce a
synergistic inhibition of in vivo tumor growth in BTCs, likely
because of a more comprehensive blockade of HER2/HER3
signaling [83]. Moreover, HER4 was found to be
overexpressed in 63.1 % of IHCCs and in 56.4 % of
EHCCs, respectively, demonstrating to be a significant poor
prognostic factor in EGFR-negative IHCC cases [81]. KRAS/
NRASmutations occur in 6.1–6.5 % of BTCs [73, 82, 85] and
they appear to be mutually exclusive with HER2 amplifica-
tion, at least in ACs [82]. Less frequently, BTCs harbor BRAF
mutations (0–8.1 %) or PI3Kmutations (7.3–10.2%) [73, 82],
while MET expression measured by IHC ranges from 5.6 to
44.1 % [54, 59, 62]. Importantly, investigational research
should mainly define magnitude and prognostic impact of
these biomarkers in BTCs and their correlation with HER2/
HER3 pathway.
Therefore, due to inherent anatomical and molecular fea-
tures, BTCs should no longer be classified as a singular entity
and, in the future, differences in tumor location or tumor biol-
ogy as well as an accurate distinction from other neoplastic
entities should be carefully considered so as to minimize dis-
appointing results in both clinical practice and scientific
research.
This systematic review and meta-analysis has limitations,
mainly linked to inter-study heterogeneity. In several studies,
a clear definition of the primary tumor site was not available or
results were not reported separately for each subgroup, thus
limiting the eligible data for inclusion in subgroup analyses.
Since no standardized techniques and scores to assess HER2
amplification and expression are available in BTCs, and be-
cause there are no internationally accepted and validated
methods for HER3 testing established in any tumor, inconsis-
tency in methodology may be an issue. Furthermore, the
Fig. 4 Correlation between
HER2 and HER3 expression
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articles included in this meta-analysis covered a long period of
time (1992 to 2015), and thus various laboratory assays were
likely utilized to determine HER2 protein expression and gene
amplification with different cutoff values for positivity
employed. Differences in methodology, disease stage (early
vs. advanced), tumor specimen (resection specimen vs. biop-
sy), site of tumor specimen (primary vs. metastases), IHC
scoring system (qualitative vs. semiquantitative), threshold
definition of IHC overexpression (provided vs. not), and/or
choice of tumors in which the ISH test was applied (HER2
overexpression vs. no overexpression) may explain the wide
range of both HER2 expression (0 to 82 %) and amplification
(0 to 100 %) positivity reported in this review. Moreover,
available literature indicates a certain variability between
polyclonal and monoclonal antibodies in the ability to detect
membranous HER2 protein, a higher level of concordance
between IHC and ISH for polyclonal antibodies, and the pos-
sibility of influencing antigen retrieval through utilization of
various applicationmethods on tissue samples [92]. Due to the
characteristics of the data reported, it was not possible to per-
form analysis of co-expression rate between HER2 and HER3
or concordance between IHC and ISH. Finally, no survival
data was available, making it impossible to assess the prog-
nostic implications of HER2/HER3 expression/amplification.
Despite the abovementioned limitations, this meta-
analysis is the first study to systematically estimate the
preva lence of HER2 and HER3 in a l l BTCs.
Approximately one fifth of EH-BTCs are HER2
overexpressed, suggesting that the development of strat-
egies against this receptor could be a reasonable thera-
peutic approach. Further data is required regarding the
impact of co-expression of both HER2 and HER3.
Standardization of ISH and IHC techniques, validation
of scoring criteria for HER2 and HER3 immunohisto-
chemistry, and assessment of concordance between IHC
and ISH, focusing on the high intra-tumoral heterogene-
ity of HER2 membranous protein [87], are needed if the
techniques are to be adopted to clinical practice.
Assuming that an overexpression of HER2 of 5 % or
less could be considered Bun-interesting,^ in this era of
personalized medicine and spending review, our data
may be particularly pertinent for the most cost-
effective selection of patients with BTCs who may ben-
efit from anti-HER2-targeted therapy.
Well-designed prospective clinical trials, for patients rigor-
ously selected by HER2-positive tumors and, possibly, strati-
fied by tumor location, are warranted to confirm the benefit of
adding anti-HER2-targeted agents to chemotherapy in ad-
vanced disease. Given the lack of benefit reported for lapatinib
in previous phase II trials in BTCs [93, 94] as well as in phase
III trials in HER2-positive advanced gastric cancer [95, 96],
alternative anti-HER2 therapies such as monoclonal antibod-
ies trastuzumab and pertuzumab seem to be more promising.
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